KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Safety and immunogenicity of a 3-dose schedule of a quadrivalent meningococcal tetanus toxoid conjugate vaccine administered concomitantly with routine pediatric vaccines to infants and toddlers: A descriptive randomized study.

Sandra Villagomez-Martinez, Susanna Kharit, Anna Galustyan, Betzana Zambrano, Mandeep Singh Dhingra, Siham B'Chir, Olga Syrkina, Olga Lyabis, Christine Rehm

Hum Vaccin Immunother 21(1) 2601413

PMID41489614
PMCIDPMC12773564
DOI10.1080/21645515.2025.2601413
发表日期2026-01-05
入排依据:未发现恶性肿瘤人群证据。
已检查 7 张 PubMed Figure,均未识别为 KM 图:Figure 1:研究设计图;Figure 2:AI 判定为 flow diagram;Figure 2:AI 判定为 flow diagram;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;另有 2 张未列出。
摘要

摘要

MenACYW-TT (MenQuadfi®), a quadrivalent meningococcal conjugate vaccine, is approved for use in individuals aged ≥12 months or ≥6 weeks depending on the country. This study reported the immunogenicity and safety of MenACYW-TT in individuals aged <12 months. This phase III, open-label, randomized, active-controlled study described the immunogenicity and safety of a 3-dose (2 + 1) immunization schedule of MenACYW-TT in Mexico and the Russian Federation or a 4-dose (3 + 1) immunization schedule of MCV4-CRM in Mexico, when co-administered with routine pediatric vaccines to healthy infants and toddlers aged 2 to 12 months (NCT03630705). The immunogenicity of meningococcal serogroups was assessed by serum bactericidal antibody assays using human complement. The safety data were collected for up to 30 d following vaccination. MenACYW-TT demonstrated high seroprotection rates in Mexico and in the Russian Federation after the last vaccination (booster) at 12 months of age. The proportion of participants achieving seroresponse to all 4 meningococcal serogroups after receiving 2 doses of MenACYW-TT in the infant series was comparable to the proportion of those receiving 3 doses of MCV4-CRM in Mexico. There was no clinically relevant effect on the immunogenicity and safety profile of the routine pediatric vaccines when administered concomitantly with MenACYW-TT at the same visit. No safety concern was observed during this study. MenACYW-TT demonstrated a safety profile generally comparable with that of MCV4-CRM when administered concomitantly with routine pediatric vaccines. The MenACYW-TT conjugate vaccine in a 2 + 1 schedule demonstrated an acceptable immunogenicity and safety profile.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(7,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Study design.
非 KM Figure
Figure 2Figure 2. Participant disposition flow chart: (a) in Mexico and (b) in the Russian Federation.
非 KM Figure
Figure 2Figure 2. (continued).
非 KM Figure
Figure 3Figure 3. Percentages of participants with hSBA titers ≥1:8 (seroprotection) 30 d after the last vaccination at 12 months of age: (a) Groups 1 and 2 in Mexico and (b) Group 3 in the Russian Federation (PPAS2).
非 KM Figure
Figure 4Figure 4. Percentages of participants with hSBA vaccine seroresponse* 30 d after the last vaccination at 12 months of age: (a) Groups 1 and 2 in Mexico and (b) Group 3 in the Russian Federation (PPAS2).
非 KM Figure
Figure 5Figure 5. Percentages of participants achieving seroprotection (hSBA titers ≥1:8) 30 d after the last vaccination of the infant series at 6 months of age: (a) Groups 1 and 2 in Mexico and (b) Group 3 in the Russian Federation (PPAS1).
非 KM Figure
Figure 6Figure 6. Percentages of participants with hSBA vaccine seroresponse* 30 d after the last vaccination of the infant series at 6 months of age: (a) Groups 1 and 2 in Mexico and (b) Group 3 in the Russian Federation (PPAS1).
非 KM Figure